AMCP Summit: Deep Dive Into Prescription Digital Therapeutics
As part of AMCP’s strategic priorities, AMCP will continue to encourage the exchange of ideas among stakeholders and initiate solutions that optimize patients’ health outcomes and address barriers to access to care. As part of this initiative, AMCP is convening a summit to bring together thought leaders to discuss digital therapeutics and share their novel, unique perspectives with managed care professionals.
This Summit was held VIRTUALLY on Thursday, June 1, 2023, from 10am ET to 4pm ET.
After attending this Summit, participants should be able to:
Explain the role of prescription digital therapeutics and the importance to managed care pharmacy professionals.
Describe established practices in evaluating the evidence surrounding digital therapeutics for formulary inclusion.
Recognize the unique distribution aspects of prescription digital therapeutics (PDTs) in relation to access to care.
Identify the barriers to the adoption of prescription digital therapeutics and possible solutions to address these barriers.
Discuss data exchange and security as it relates to prescription digital therapeutics.
Agenda and Registration:
Please note that information about this Summit will be updated regularly.
Susan A. Cantrell, MHL, RPh, CAE
Chief Executive Officer
Dan Leonard, MA
Granite Capitol Consulting
Digital Therapeutics 101
What are PDTs compared to digital therapeutics? How are PDTs authorized by the Food and Drug Administration? Discover which products are currently available, where the pipeline is headed, and how digital therapeutics impact managed care pharmacy and ultimately affects patient access and the value of these products.
Jeffrey Abraham, MSPT, MBA
Vice President, Digital Health Practice Co-Lead
Allyson Mullen, JD
Hyman, Phelps & McNamara P.C.
Established Practices in Evaluating Data and Formulary Development for Digital Therapeutics
How are digital therapeutics integrated in managed care organizations for coverage benefits? What are significant differences to consider when reviewing a digital therapeutic compared to a traditional drug? This session will explain the process of how health plans and PBMs address these topics in addition to potential solutions to overcome future challenges that may hinder the managed care organization’s inclusion of this regulated, innovative product.
Adam Hoye-Simek, PharmD, RPh
Senior Pharmacy Manager of Utilization Management
Devoted Health Plan
Theresa Juday, RPh
Director, Specialty Product Development
Gail Ryan, PharmD
Director of Pharmaceutical Transformation
Mahsa Salsabili, PharmD, PhD
ForHealth Consulting | UMass Chan Medical School
Operationalizing Prescription Digital Therapeutics: Challenges and Solutions to Adoption
PDTs carry several challenges when evaluating their application in payment models, some of which include: what changes need to be made to existing compendia and how will health outcomes be monitored? What needs to evolve between the patient and sponsor relationship to enable pharmacy reimbursement? Follow the journey from the diagnosis to patient access in this session that will describe the areas of success and opportunity related to PDTs.
General Manager & Head, Pfizer Digital Health & Medicines
Ann Johnson, PharmD
Pharmacy Healthcare Solutions, LLC
Rob O’Brien, RPh
Senior Vice President, Specialty Pharmacy
Benjamin Parcher, PharmD, MS
Global Market Access Lead, CNS Digital Therapeutics
Boehringer Ingelheim Pharmaceuticals, Inc.
Scott Whittle, MD
Chief Medical Officer
Prescription Digital Therapeutics Data Exchange and Security
What components of PDT data exchange are important for managed care organizations to be aware of? How do payers evaluate adherence or engagement and what data security guidelines are available? Key components of PDTs will be discussed involving data exchange and security, including encryption, infrastructure, and certification.
Titi Ala’ilima, MSE
VP Applied Data
Akili Interactive Labs, Inc.
C. Lucas Beal, JD
Jessilyn Dunn, PhD
David Putrino, PhD, PT
Icahn School of Medicine at Mount Sinai
What have you learned regarding digital therapeutics and its future? What gains have been and what challenges still exist in anticipation of the evolving pipeline? Join us in the closing of the AMCP Summit: Deep Dive into Prescription Digital Therapeutics!
AMCP Registration Fees:
- AMCP Member: Free
- Non-Member: $125
Thank you to the sponsors of AMCP Summit: Deep Dive Into Prescription Digital Therapeutics.